FDMT
4D Molecular Therapeutics In
NASDAQ · Biotechnology
$8.99
+0.60 (+7.15%)
Open$8.50
Previous Close$8.39
Day High$9.00
Day Low$8.42
52W High$12.34
52W Low$2.24
Volume—
Avg Volume851.1K
Market Cap458.56M
P/E Ratio—
EPS$-3.74
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+134.8% upside
Current
$8.99
$8.99
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 35.7K | 280.9K | 256.30M |
| Net Income | -152,110,585 | -1,077,100,916 | -65,224,635 |
| Profit Margin | -434,778.4% | -413,039.5% | -25.5% |
| EBITDA | -173,289,055 | -1,295,236,839 | -118,507,398 |
| Free Cash Flow | — | — | -99,529,069 |
| Rev Growth | -87.3% | -87.3% | +0.0% |
| Debt/Equity | — | — | 0.11 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |